We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -106.00 | -0.87% | 12,050.00 | 12,036.00 | 12,038.00 | 12,178.00 | 12,010.00 | 12,092.00 | 1,635,146 | 16:35:23 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.34 | 186.61B |
From May 2021 to May 2024
By Ian Walker
AstraZeneca PLC said Tuesday that the European Commission has conditionally approved Koselugo in the European Union for children with neurofibromatosis type 1 and plexiform neurofibromas.
The pharmaceutical giant said that Koselugo reduced tumor volume, pain and improved life quality in a Sprint Phase 2 trial.
Neurofibromatosis type 1 is a rare and debilitating genetic condition affecting one in 3,000 individuals world-wide.
Koselugo is already approved in the U.S. and several other countries for the treatment of pediatric patients with NF1 and symptomatic, inoperable plexiform neurofibromas.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
June 22, 2021 02:29 ET (06:29 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
